West Pharmaceutical Services shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $390 to $405.
Portfolio Pulse from Benzinga Newsdesk
Bank of America Securities upgraded West Pharmaceutical Services from Neutral to Buy and raised its price target from $390 to $405.
June 16, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
West Pharmaceutical Services stock upgraded to Buy by BofA Securities with a raised price target of $405.
The upgrade from Neutral to Buy by Bank of America Securities and the raised price target from $390 to $405 indicate a positive outlook for West Pharmaceutical Services. This is likely to have a positive short-term impact on the stock price as investors may see this as a signal to buy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100